← Russell 3000 cross-section

IBRX ImmunityBio, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$9.0bn
Revenue TTM
$166m
Net income TTM
$-992m
Free cash flow
$-288m
Composite score
Sector rank
#770

Valuation

P / E
EV / EBITDA
EV / sales
51.9
FCF yield
-3.21%
Earnings yield vs 10-yr
-15.80pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-598.6%
EBITDA margin
-141.9%
ROE
94.8%
ROIC
Revenue growth
192.9%

Insider activity, last 90 days

Net open-market
$-3.92m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Product Revenue, Net Product revenue, net increased $24.3 million during the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, due to an increase in sales of ANKTIVA. Other Revenues Other revenues increased $0.6 million during the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, primarily due to increased bioreactor and related consumable product sales. ImmunityBio, Inc. …ImmunityBio, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →